



BEXIMCO PHARMACEUTICALS LTD.

News Release

August, 2009

Beximco Pharma launches six eye care products

Beximco Pharmaceuticals Ltd. (BPL or the company), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh, has diversified its activities into ophthalmology area.

Beximco Pharma Vision, the newly established unit of the company, launched six eye care products to make a big difference in the lives of people in Bangladesh.

The products are **Neofloxin**[®] (Ciprofloxacin) eye/ear drops, **Tofen**[®] (Ketotifen) eye drops, **Inflavis**[®] (Dexamethasone) eye/ear drops, **Intramol**[®] (Timolol) eye drops, **Ocutrex**[®] (Chloramphenicol) eye/ear drops and **Tearon**[®] (Polyethylene glycol & Propylene glycol) eye drops, an official statement of the company said.

Neofloxin[®] eye/ear drops is a preparation of Ciprofloxacin 0.3%, is helpful for the treatment of various eye and ear infections. **Tofen**[®] eye drops, a preparation of Ketotifen 0.025%, indicated for all type of allergic conjunctivitis.

Meanwhile, **Inflavis**[®] eye/ear drops, a preparation of Dexamethasone 0.1%, is a potent anti-inflammatory agent with multiple benefits. **Intramol**[®] eye drops (Timolol 0.5%) is a safe & prompt acting non-selective beta blocker for glaucoma and ocular hypertension.

Ocutrex[®] eye/ear drops (Chloramphenicol 0.5%) tested & trusted for acute bacterial infections and **Tearon**[®] eye drops (Polyethylene glycol 400 0.4% & Propylene glycol 0.3%) is a fast-acting and long-lasting eye lubricant for dry eyes.

Beximco Pharma Vision uses the most modern equipment for quality control and stringent quality assurance procedure to ensure highest quality of eye products. Beximco Pharma Vision's manufacturing process conforms strictly to the current Good Manufacturing Practices (cGMP) to produce world class ophthalmic products. In addition to the launched brands a number of much needed products will be introduced in the coming months to cater to the need of eye specialists.

On the occasion of launching ophthalmic products, Beximco Pharma Managing Director Mr. Nazmul Hassan said, "From its very inception, Beximco Pharma has been a technology driven pharmaceutical company and has always been very prompt in introducing new high-tech formulations in Bangladesh. BPL was the first company in Bangladesh to introduce high-tech Intravenous fluids with auto-collapsible bottle using state-of-the-art Form-Fill-Seal technology, MDI technology and is also the first to switch

to CFC-free advanced technology HFA based MDIs. I think the introduction of eye products in Bangladesh is in line with this inherent urge for innovation and a number of much needed quality products will be introduced in the coming months.”

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,300 staff.

The Company’s products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Pakistan, Nepal, Bhutan and Myanmar and in other markets overseas, principally in East Africa and South East Asia, including Singapore.

Beximco Pharma is the only Bangladeshi company to receive GMP Certification from Gulf Central Committee for Drug Registration, Executive Board of the Health Ministers' Council for GCC states and first Bangladeshi company to receive GMP Clearance from Therapeutic Goods Administration (TGA), Australia.

End